Surgical management of ovarian cancer

Seminars in Surgical Oncology

Volumn 17, Issue 3, 1999, Pages 173-180

  Randall, Thomas C ^a,b   Rubin, Stephen C ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b 1000 Courtyard Building ^*  (United States)

Author keywords

Adenocarcinoma; Adnexal diseases; Biopsy; CA 125 antigen; Combined antineoplastic agents; Laparoscopy; Lymph nodes; Mass screening; Neoplasm metastasis; Neoplasm staging; Ovarian neoplasms etiology diagnosis surgery pathology drug therapy; Quality of life; Survival rate

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; HORMONE; PLATINUM COMPLEX;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; DISEASE COURSE; FEMALE; HORMONE SUBSTITUTION; HUMAN; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME;

CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; NEOPLASM STAGING; OVARIAN NEOPLASMS;

EID: 0032829766     PISSN: 87560437     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2388(199910/11)17:3<173::AID-SSU6>3.0.CO;2-5     Document Type: Review

References (45)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Scully RE, Bonfiglio TA, Kurman RJ, et al: "Histological typing of female genital tract tumours. (International histologic classification of tumors.) 2nd ed. NY: Springer-Verlag; 1994.
3. Rubin SC, Lewis JL Jr: Second-look surgery in ovarian cancer [Review]. Crit Rev Oncol Hematol 1988;8:75-91.
4. International Federation of Gynecology and Obstetrics Cancer Committee. Staging announcement. Gynecol Oncol 1986;25:383-385.
5. Kadar N: Port-site recurrences following laparoscopic operations for gynaecological malignancies. Br J Obstet Gynaecol 1997; 104:1308-1313.
6. Bourne T, Campbell S, Steer C, et al: Transvaginal colour flow imaging: a possible new technique for ovarian cancer. BMJ 1989;299(6712):1367-1370.
7. DePriest PD, Gallion HH, Pavlik EJ, et al: Transvaginal sonography as a screening method for the detection of early ovarian cancer [Review]. Gynecol Oncol 1997;65:408-414.
8. Chi DS, Curtin JP, Barakat RR: Laparoscopic management of adnexal masses in women with a history of nongynecologic malignancy. Obstet Gynecol 1995;86:964-968.
9. National Insitutes of Health Consensus Development Conference Statement. Ovarian cancer: screening, treatment, and follow-up [Review]. Gynecol Oncol 1994;55(3 Pt 2):S4-S14.
10. Piver MS, Barlow JJ, Lele SB: Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol 1978;52:100-104.
11. Musumeci R, De Palo G, Kenda R, et al: Retroperitoneal metastases from ovarian carcinoma: reassessment of 365 patients studied with lymphography. AJR Am J Roentgenol 1980;134:449-452.
12. Munoz KA, Harlan LC, Trimble EL: Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 1997;15:3408-3415.
13. McGowan L, Lesher LP, Norris HJ, Barnett M: Misstaging of ovarian cancer. Obstet Gynecol 1985;65:568-572.
14. Young RC, Decker DG, Wharton JT, et al: Staging laparotomy in early ovarian cancer. JAMA 1983;250:3072-3076.
15. Buchsbaum HJ, Brady MF, Delgado G, et al: Surgical staging of ovaries. Surg Gynecol Obstet 1989;169:226-232.
16. Benjamin I, Morgan MA, Rubin SC: Occult bilateral involvement in stage I epithelial ovarian cancer. Gynecol Oncol 1999;72: 288-291.
17. Raspagliesi F, Fontanelli R, Paladini D, di Re EM: Conservative surgery in high-risk epithelial ovarian carcinoma. J Amer Coll Surg 1997;185:457-460.
18. Griffiths CT: Surgery at the time of diagnosis in ovarian cancer. In Blackledge G, Chan KK (eds): "Management of ovarian cancer." London: Butterworths; 1986. p. 60.
19. Skipper HE: Thoughts on cancer chemotherapy and combination modality therapy (1974). JAMA 1974;230:1033-1035.
20. Goldie JH, Coldman AJ: A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep 1979;63:1727-1733.
21. Munnell EW: The changing prognosis and treatment in cancer of the ovary. A report of 235 patients with primary ovarian carcinoma 1952-1961. Am J Obstet Gynecol 1968;100:790-805.
22. Griffiths CT: Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 1975; 42:101-104.
23. Omura GA, Bundy BN, Berek JS, et al: Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1989;7:457-465.
24. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA: The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 1992;47:159-166.
25. Pohl R, Dallenbach-Hellweg G, Plugge T, Czernobilsky B: Prognostic parameters in patients with advanced ovarian malignant tumors. Eur J Gynaecol Oncol 1984;3:160-169.
26. Conte PF, Sertoli MR, Bruzzone M, et al: Cisplatin, methotrexate and 5-fluorouracil combination chemotherapy for advanced ovarian cancer. Gynecol Oncol 1985;20:290-297.
27. Posada JG Jr, Marantz AB, Yeung KY, et al: The cyclophosphamide, hexamethylmelamine, 5 fluorouracil (CHF) regimen in the treatment of advanced and recurrent ovarian cancer. Gynecol Oncol 1985;20:23-31.
28. Sutton GP, Stehman FB, Einhorn LH, et al: Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 1989;7:223-229.
29. Redman JR, Petroni GR, Saigo PE, et al: Prognostic factors in advanced ovarian carcinoma. J Clin Oncol 1986;4:515-523.
30. Piver MS, Lele SB, Marchetti DL, et al: The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma. J Clin Oncol 1988;6:983-989.
31. Vogl SE, Pagano M, Kaplan BH, et al: Cis-platin based combination chemotherapy for advanced ovarian cancer. High overall response rate with curative potential only in women with small tumor burders. Cancer 1983;51:2024-2030.
32. Delgado G, Oram DH, Petrilli ES: Stage III epithelial ovarian cancer: the role of maximal surgical resection. Gynecol Oncol 1984;18:293-298.
33. Conte PF, Bruzzone M, Chiara S, et al: A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer [published erratum appears in J Clin Oncol 1986;4:1284]. J Clin Oncol 1986;4:965-971.
34. Seifer DB, Kennedy AW, Webster KD, et al: Outcome of primary cytoreduction surgery for advanced epithelial ovarian cancer. Clev Clin J Med 1988;55:555-560.
35. Curtin JP, Malik R, Venkatraman ES, et al: Stage IV ovarian cancer: impact of surgical debulking. Gynecol Oncol 1997;64:9-12.
36. Liu PC, Benjamin I, Morgan MA, et al: Effect of surgical debulking on survival in stage IV ovarian cancer. Gynecol Oncol 1997;64:4-8.
37. Munkarah AR, Hallum AV 3rd, Morris M, et al: Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer. Gynecol Oncol 1997;64:13-17.
38. Bristow RE, Montz FJ, Lagasse LD, et al: Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol 1999;72:278-287.
39. Venesmaa P, Ylikorkala O: Morbidity and mortality associated with primary and repeat operations for ovarian cancer. Obstet Gynecol 1992;79:168-172.
40. Eisenkop SM, Friedman RL, Wang HJ: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69:103-108.
41. Goodman HM, Harlow BL, Sheets EE, et al: The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma. Gynecol Oncol 1992;46:367-371.
42. Blythe JG, Wahl TP: Debulking surgery: does it increase the quality of survival? Gynecol Oncol 1982;14:396-408.
43. van der Burg ME, van Lent M, Buyse M, et al: The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. N Engl J Med 1995;332: 629-634.
44. Nelson BE, Rosenfield AT, Schwartz PE: Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma. J Clin Oncol 1993; 11:166-172.
45. Schwartz PE, Chambers JT, Makuch R: Neoadjuvant chemotherapy for advanced ovarian cancer. Gynecol Oncol 1994;53:33-37.